RCT | Low-dose immunotherapy (nivolumab) may improve outcomes when added to chemotherapy for head and neck cancer.

Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary from the author on Twitter

Low-Dose Immunotherapy has made immunotherapy more accessible, and has brought down the cost of therapy from 60-80 lakhs to below 5.0 lakhs per year. Hugh cost saving. A step towards atmanirbhar Bharat. @PMOIndia @TOIIndiaNews @ndtv @ZeeNews @the_hindu https://t.co/c0WuC9Wlfk

— Dr. Vijay Patil (@DrVijayPatil11) October 21, 2022